# Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

> **NCT06359002** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Byondis B.V.** · enrollment: 16 (actual)

## Conditions studied

- Relapsed / Refractory AML
- Relapsed / Refractory MDS

## Interventions

- **DRUG:** BYON4413

## Key facts

- **NCT ID:** NCT06359002
- **Lead sponsor:** Byondis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-25
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06359002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06359002, "Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06359002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*